All In Biotech

Free tool

FAERS Monitor: Rituxan Hycela

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761064 or its brand name (Rituxan Hycela, Rituximab, Hyaluronidase (Human Recombinant)). Reports on generic versions are filed under their own applications.

Reports

453

Serious

159

35% of reports

Hospitalization

66

Death reported

42

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • no adverse event88
  • off label use82
  • rash50
  • fatigue36
  • nausea35
  • pain33
  • headache28
  • dizziness27
  • pneumonia27
  • dyspnoea26
  • diarrhoea25
  • intentional product use issue25
  • malaise24
  • visual impairment24
  • pruritus23

Reports by year received

View as table
YearReports
20152
201724
201871
201967
202073
202144
202234
202334
202459
202528
202617

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,706 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
no adverse eventSignal8822.618.71,806
intentional product use issueSignal2513.39.1272
visual impairmentSignal249.06.1164
rashSignal505.34.1175
off label useSignal824.33.6217
pneumoniaSignal273.92.756
pruritusSignal232.81.925
malaiseSignal242.51.721
dizzinessSignal272.51.724
painSignal332.51.829
fatigueSignal362.11.622
dyspnoeaSignal262.11.515
headacheSignal282.11.415
nauseaSignal352.11.519
diarrhoea251.81.28

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.